Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 1;120(23):3660-8.
doi: 10.1002/cncr.28930. Epub 2014 Jul 17.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

Michael E Rytting  1 , Deborah A Thomas, Susan M O'Brien, Farhad Ravandi-Kashani, Elias J Jabbour, Anna R Franklin, Tapan M Kadia, Naveen Pemmaraju, Naval G Daver, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Y Konopleva, Jorge E Cortes, Gautham Borthakur, Rebecca Garris, Maria Cardenas-Turanzas, Kurt Schroeder, Jeffrey L Jorgensen, Steven M Kornblau, Hagop M Kantarjian
Affiliations

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

Michael E Rytting et al. Cancer. .

Abstract

Background: Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The results were compared with those from a similar population that received the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen.

Methods: Eighty-five patients ages 12 to 40 years who had Philadelphia chromosome (Ph)-negative ALL received the ABFM regimen from October 2006 through April 2012. Their outcome was compared with outcomes in 71 historic AYA patients who received hyper-CVAD from the authors' institution. Patient and disease characteristics, as well as minimal residual disease status, were analyzed for their impact on outcomes.

Results: The complete response rate with ABFM was 94%. The 3-year complete remission duration (CRD) and overall survival (OS) rates were 70% and 74%, respectively. For patients aged ≤21 years, the 3-year CRD and OS rates were 72% and 85%, respectively; and, for patients ages 21 to 40 years, the respective rates were 69% and 60%. The initial white blood cell count was an independent predictive factor of OS and CRD. The minimal residual disease status on days 29 and 84 of therapy also were predictive of long-term outcomes. Severe regimen toxicities included transient hepatotoxicity in 35% to 39% of patients, pancreatitis in 11% of patients, osteonecrosis in 11% of patients, and thrombosis in 22% of patients. The 3-year OS rate was 74% in the ABFM group versus 71% in the hyper-CVAD group, and the corresponding 3-year CRD rate was 70% versus 66%, respectively.

Conclusions: ABFM was tolerable in AYA patients with ALL but was not associated with significant improvements in CRD and OS compared with hyper-CVAD.

Keywords: Philadelphia chromosome-negative ALL; acute lymphoblastic leukemia; augmented Berlin-Frankfurt-Münster; pediatric-based regimens; pediatric-based therapy.

PubMed Disclaimer

Figures

Figure 1A-1D
Figure 1A-1D
Kaplan Meier curves of Overall Survival and Complete Remission Duration by age and day 29 minimal residual disease.
Figure 2A-2D
Figure 2A-2D
Kaplan Meier curves of Overall Survival and Complete Remission Duration by presenting WBC and by protocol.
See this image and copyright information in PMC

References

    1. Stock W, La M, Bloomfield CD, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? Blood. 2008;112(5):1646. - PMC - PubMed
    1. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children of young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774. - PubMed
    1. Ramanujachar R, Richards S, Hans I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48(3):254. - PubMed
    1. Ram R, Wolach O, Vidal L, et al. Addolescents and young adults with acute luymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012 May;87(5):472–8. - PubMed
    1. Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic Leukemia in adolescents and young adults in Finland. Haematologica. 93(8):1161–8. - PubMed

MeSH terms

Supplementary concepts